A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback